- Assignment Description At some point in your life someone you care about, or you yourself, may to become ill.
Should this happen you will have to interact with some level of health care as you attempt to ensure that you or your loved one is getting the best care possible. While you can use sources like the internet or textbooks to learn about the disease you are dealing with and it’s treatment strategies there is incredible value in being able to research the actual efficacy of specific treatments that are being recommended. The best way to get this information is to look at primary research studies that present hard data on how effective, or ineffective, a specific treatment may be.
For your first assignment in KNPE 125 you are being asked to put together an annotated bibliography describing 4 primary research articles and what they tell you about the whether or not the treatment being studied is one that appears to effectively treat the disease in question. As we have just finished a unit on the nervous system you will be asked to examine a specific treatment for a disease that effects the nervous system.
Below, you will find a list of 11 topics covering 1 or 2 treatment strategies for 6 different diseases of the central nervous system. Each topic is accompanied by 2 references that are to be used at the first 2 citations in your annotated bibliography. You will also have to find and annotate 2 additional references on the same topic as the 2 references provided. All references must be original research reports.
You must sign up for a topic on the course Moodle page any time after 12:30 on Friday,
February 7th. There are limited spaces within each topic so if you really want to work on a specific topic sign up early!
- Assignment Topics and References Treatment of Multiple Sclerosis (MS) with intramuscular interferon
Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BMJ, Casset-Semanaz F,
Hennessy B, Moraga MS, Rocak S, Stubinski B and Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11: 33–41, 2012.
Ebers G. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing / remitting multiple sclerosis. Lancet 352: 1498 – 1504, 1998.
Treatment of Multiple Sclerosis (MS) with oral and intramuscular fingolimod
Cohen J, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P,
Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S and Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 362: 402–15, 2010.
Kappos L and Radue E. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New
Engl J Med 362: 387–401, 2010.
Treatment of amyotrophic lateral sclerosis (ALS) with Riluzole
Bensimon G. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 330: 585–91,
Lacomblez L, Bensimon G and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431, 1996.
Treatment of amyotrophic lateral sclerosis (ALS) with Tirasemtiv
Shefner JM, Watson ML, Meng L and Wolff A. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler
Frontotemporal Degener 14: 574–81, 2013.
Shefner J, Wolff AA and Meng L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph Lateral Scle Frontotemporal Degener 582–585,
Treatment of Parkinson’s Disease with deep brain stimulation
Rodriguez-Oroz MC, Obeso J, Lang E, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A,
Volkmann J, Hariz MI, Quinn NP, Speelman JD,